Jaime Merchan, MD, discusses the background and findings from the LITESPARK-013 trial of belzutifan for the treatment of patients with advanced clear cell renal cell carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback